Genetic Polymorphism inN-Acetyltransferase (NAT): Population Distribution of NAT1 and NAT2 Activity
Authors:
- 6 October 2009
- journal article
- research article
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part B
- Vol. 12 (5-6) , 440-472
Abstract
N-Acetyltransferases (NAT) are key enzymes in the conjugation of certain drugs and other xenobiotics with an arylamine structure. Polymorphisms in NAT2 have long been recognized to modulate toxicity produced by the anti-tubercular drug isoniazid, with molecular epidemiologic studies suggesting a link between acetylator phenotype and increased risk for bladder cancer. Recent evidence indicates that the other major NAT isozyme, NAT1, is also polymorphic. The current analysis characterizes the main polymorphisms in both NAT2 and NAT1 in terms of their effect on enzyme activity and frequency in the population. Multiple NAT2 alleles (NAT2∗5, ∗6, ∗7, and ∗14) have substantially decreased acetylation activity and are common in Caucasians and populations of African descent. In these groups, most individuals carry at least one copy of a slow acetylator allele, and less than 10% are homozygous for the wild type (fast acetylator) trait. Incorporation of these data into a Monte Carlo modeling framework led to a population distribution of NAT2 activity that was bimodal and associated with considerable variability in each population assessed. The ratio of the median to the first percentile of NAT2 activity ranged from 7 in Caucasians to 18 in the Chinese population. This variability indicates the need for more quantitative approaches (e.g., physiologically based pharmacokinetic [PBPK] modeling) to assess the full distribution of internal dose and adverse responses to aromatic amines and other NAT2 substrates. Polymorphisms in NAT1 are generally associated with relatively minor effects on acetylation function, with Monte Carlo analysis indicating less interindividual variability than seen in NAT2 analysis.Keywords
This publication has 107 references indexed in Scilit:
- Colon tumor mutations and epigenetic changes associated with genetic polymorphism: Insight into disease pathwaysMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009
- Tissue Expression and Genomic Sequences of Rat N-acetyltransferases rNat1, rNat2, rNat3, and Functional Characterization of a Novel rNat3*2 Genetic VariantToxicological Sciences, 2007
- Characterization of N-acetyltransferase 1 and 2 polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinomaBMC Medical Genetics, 2007
- Contribution of the N-acetyltransferase 2 polymorphism NAT2*6A to age-related hearing impairmentJournal of Medical Genetics, 2007
- Identification of N-Acetyltransferase 2 (NAT2) Transcription Start Sites and Quantitation of NAT2-Specific mRNA in Human TissuesDrug Metabolism and Disposition, 2007
- Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2Carcinogenesis, 2007
- Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2Pharmacogenetics and Genomics, 2007
- Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphomaPharmacogenetics and Genomics, 2006
- NAT2 slow acetylator genotype as an important modifier of breast cancer riskInternational Journal of Cancer, 2004
- Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populationsPharmacogenetics, 1996